Researchers are getting closer to adding another tool to the treatment regimen of individuals living with HIV that would be able to deliver HIV treatments through a long-acting, refillable nanofluidic implant that delivers an HIV antiviral medication. (Credit: Houston Methodist)

A nanofluidic implant delivered an HIV drug that achieved more potency than other forms of drug administration (oral) and other HIV drugs.

The results of a recent may lead to a long-acting, refillable implant that delivers an HIV antiviral medication, Islatravir, into humans living with human immunodeficiency virus (HIV), a chronic yet manageable disease. The research focused on the potency, efficacy, and tolerability of the drug when subcutaneously administered at a low dose in a continuous manner.

The potency of continuous, subdermal elution of Islatravir was fivefold higher than cabotegravir, an intramuscular injectable antiviral for HIV prevention and treatment.

The nanofluidic device is intended for long-term controlled and sustained release, avoiding repeated systemic treatment that often leads to adverse side effects. Additional lab research is under way to determine the effectiveness and safety of this delivery technology, but researchers would like to see this become a viable option for HIV patients in the next few years.